
|Articles|October 15, 2003
AAO makes case for OPT for Medicare patients
Washington, DC-The Medicare Coverage Advisory Committee has voted overwhelmingly in favor of making ocular photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) available as a valid and important treatment for treating AMD in select patients with subfoveal choroidal neovascularization (CNV) with occult but no classic CNV.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
Ocumetics reports first-in-human data investigational accommodating IOL in severe vision loss
3
China's NMPA approves ZEISS ARTEVO 750 and ARTEVO 850 ophthalmic surgical microscopes for clinical use
4
Last year in glaucoma at EnVision Summit 2025
5




























